Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Differentiation antagonizing non-protein coding RNA (DANCR), also known as ANCR, is a long non-coding RNA (lncRNA) that plays a critical role in maintaining the undifferentiated state of progenitor cells by suppressing premature differentiation (Kretz et al., 2012, Nature, https://pubmed.ncbi.nlm.nih.gov/22343891/). In various malignancies, DANCR is significantly upregulated and acts as a potent oncogene, promoting cell proliferation, migration, and invasion while inhibiting apoptosis (Thin et al., 2018, Frontiers in Oncology, https://www.frontiersin.org/articles/10.3389/fonc.2018.00312/full). It functions primarily as a competitive endogenous RNA (ceRNA), sponging microRNAs such as miR-33a-5p and miR-214 to modulate the expression of downstream oncogenic targets (Liu et al., 2018, Journal of Experimental & Clinical Cancer Research, https://jeccr.biomedcentral.com/articles/10.1186/s13046-018-0982-0). Additionally, DANCR interacts with the Polycomb Repressive Complex 2 (PRC2) through its association with EZH2, leading to the epigenetic silencing of tumor suppressor genes (Jia et al., 2016, Scientific Reports, https://www.nature.com/articles/srep36673). Due to its overexpression in cancer and its correlation with poor patient prognosis, DANCR is being investigated as both a diagnostic biomarker and a therapeutic target. Experimental strategies to inhibit DANCR include the use of antisense oligonucleotides (ASOs) and siRNA-mediated knockdown, which have shown efficacy in reducing tumor growth in preclinical models (Lu et al., 2018, Molecular Cancer, https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-018-0842-y).
Competitive endogenous RNA (ceRNA) / microRNA sponging and recruitment of chromatin-modifying complexes like PRC2 to epigenetically regulate gene expression (Thin et al., 2018, Frontiers in Oncology, https://www.frontiersin.org/articles/10.3389/fonc.2018.00312/full).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Differentiation antagonizing non-protein coding RNA (DANCR) (DANCR).